Menu U.S. stocks struggle for direction after a round of record highs – Tehuty Finance

U.S. stocks struggle for direction after a round of record highs

0


U.S stocks were little changed on opening Friday, struggling for direction after benchmark indexes closed at record highs in the previous session, with investors focused on talks in Washington over another round of economic relief.

What are major benchmarks doing?
  • The Dow Jones Industrial Average
    DJIA,
    -0.03%

    rose 16.61 points, a gain of less than 0.1%, to trade at 30,319.98.

  • The S&P 500
    SPX,
    -0.10%

    ticked up 1.07 point to 3,723.55.

  • The Nasdaq Composite COMP rose 26.56 points, or 0.2%, to 12,791.31.

Stocks rose modestly Thursday, with gains carrying the Dow, S&P 500, Nasdaq Composite and the small-cap Russell 2000
RUT,
+1.30%

to record finishes.

What’s driving the market?

Republican and Democratic lawmakers continued to negotiate toward a $900 billion package of economic relief that would send checks to households, extend unemployment benefits and provide aid to small businesses. At the same time, a midnight Friday deadline to complete a bill funding government operations loomed, leaving the possibility of a government shutdown in the midst of a worsening pandemic.

Still, the path of least resistance for equities may remain to the upside on continued expectations that a worsening economic backdrop, as illustrated by a Thursday rise in first-time jobless claims data, will push Congress to complete a deal, analysts said.

“Lawmakers from both major U.S. political parties said that failing to agree on a COVID-relief package is not an option, while Republican Senate Majority Leader Mitch McConnell said that talks could spill into the weekend,” said Charalambos Pissouros, senior market analyst at JFD Group, in a note. “In our view, this suggests that a bill is more likely than not to pass before the end of the year. ”

Meanwhile, a second COVID-19 vaccine is expected to soon be rolled out. An independent advisory committee on Thursday voted 20-0-1 that the benefits of Moderna Inc.’s
MRNA,
-3.14%

COVID-19 vaccine candidate outweigh the risks, a recommendation that sets the stage for a likely Food and Drug Administration authorization. Moderna shares were down 1.7%.

Inoculations using the vaccine developed by Pfizer Inc.
PFE,
-0.27%

and BioNTech SE
BNTX,
-0.86%

began earlier this week.

There were 238,189 new COVID-19 cases reported in the U.S. on Thursday, down slightly from 245,033 on Wednesday, according to data provided by the New York Times. Deaths fell from Wednesday’s record of 3,611 to at least 3, 293 on Thursday, remaining above the 3,000 level for a third straight day.

The U.S. economic calendar is light to end the last full trading week of 2020. The current-account deficit, a measure of the nation’s debt to other countries, rose 10.6% in the third quarter largely because of an increase in the trade gap on goods.

A reading on leading economic indicators from the Conference Board for November is due at 10 a.m. Eastern.

Which companies are in focus?
What are other markets doing?
  • In Asia, the Shanghai Composite
    SHCOMP,
    -0.29%

    fell 0.3%, Hong Kong’s Hang Seng Index
    HSI,
    -0.67%

    lost 0.7% and Japan’s Nikkei 225
    NIK,
    -0.16%

    shed 0.2%.

  • In Europe, the Stoxx 600 Europe
    SXXP,
    -0.06%

    was flat, while London’s FTSE 100 stock index
    UKX,
    +0.10%

    edged up 0.1%.

  • The 10-year Treasury note yield
    TMUBMUSD10Y,
    0.929%

    was off 0.4 basis point at 0.924%. Yields and prices move in opposite directions.

  • Oil futures edged higher, with the U.S. benchmark
    CL.1,
    +0.93%

    up 0.8% and on track for a seventh straight weekly rise.

  • Gold futures
    GC00,
    -0.05%

    were under pressure, but on track for a weekly rise.


Leave A Reply

Your email address will not be published.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More